SORIN CRM SAS (Microport CRM)

Cardiovascular medicine

The sponsor’s clinical research is centered on acute myocardial infarction, with attention to patients recovering after a heart attack and undergoing complete revascularization.

  • Acute myocardial infarction
  • Heart attack recovery
  • Coronary revascularization

Its work is directed toward treatment strategies for clinically stable patients with low to moderate lesion complexity in the setting of coronary artery disease.

Antiplatelet therapy

Research activity includes modified antiplatelet therapy aimed at reducing thrombotic risk after coronary intervention in patients with myocardial infarction.

  • Antiplatelet treatment
  • Platelet aggregation inhibition
  • Post-intervention thrombosis prevention

This area reflects interest in balancing clot prevention with safety in patients managed after coronary revascularization.

Drug-eluting stent therapy

The sponsor is involved in studies of drug-eluting stents, including the Firehawk platform, in the context of coronary artery treatment.

  • Drug-eluting stents
  • Coronary stent implantation
  • Stenosed blood vessel management

Its clinical focus includes device-based therapy for maintaining vessel patency after treatment of obstructive coronary lesions.

Interventional cardiology

Clinical interest extends to the post-procedural management of patients treated with coronary interventions across multiple research sites in Europe.

  • Coronary intervention
  • Post-stent management
  • Multicenter cardiovascular research

The sponsor’s research landscape links device therapy and medical treatment in the care of patients with acute coronary syndromes.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study of Modified Anti-Platelet Therapy with Prasugrel, Ticagrelor, and Clopidogrel in Heart Attack Patients Undergoing Complete Revascularization

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Italy The Netherlands Spain